XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue from Contracts with Customers (Tables)
6 Months Ended
Jun. 30, 2022
Revenue from Contracts with Customers  
Summary of product revenue provision and allowance

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance at December 31, 2021

$

142,379

$

54,617

$

13,226

Acquired from BDSI

38,074

18,187

7,575

Provision related to current period sales

233,089

16,675

59,211

Changes in estimate related to prior period sales

(481)

(37)

Credits/payments made

(244,356)

(11,465)

(52,939)

Balance at June 30, 2022

$

168,705

$

78,014

$

27,036

    

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance at December 31, 2020

$

132,775

$

23,779

$

19,055

Provision related to current period sales

179,571

7,491

42,059

Changes in estimate related to prior period sales

(441)

Credits/payments made

(178,508)

(21,443)

(33,764)

Balance at June 30, 2021

$

133,397

$

9,827

$

27,350

(1)Provisions for rebates and incentives includes managed care rebates, government rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Consolidated Balance Sheets.
(2)Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Consolidated Balance Sheets.
(3)Provisions for trade allowances and chargebacks include fees for distribution service fees, prompt pay discounts, and chargebacks. Trade allowances and chargebacks are deducted from gross revenue at the time revenues are recognized and are recorded as a reduction to accounts receivable in the Company’s Consolidated Balance Sheets.
Schedule of disaggregation of revenue

Three Months Ended June 30,

Six Months Ended June 30,

2022

2021

2022

2021

Belbuca

$

42,301

$

$

45,611

$

Xtampza ER

33,190

    

33,023

64,708

68,432

Nucynta IR

26,554

29,241

55,889

59,767

Nucynta ER

17,077

20,678

36,340

42,464

Symproic

3,860

4,160

Elyxyb

109

134

Other

458

458

Total product revenues, net

$

123,549

$

82,942

$

207,300

$

170,663